<?xml version='1.0' encoding='utf-8'?>
<document id="30758919"><sentence text="Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers."><entity charOffset="0-9" id="DDI-PubMed.30758919.s1.e0" text="Lesinurad" /><entity charOffset="79-87" id="DDI-PubMed.30758919.s1.e1" text="Warfarin" /><pair ddi="false" e1="DDI-PubMed.30758919.s1.e0" e2="DDI-PubMed.30758919.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30758919.s1.e0" e2="DDI-PubMed.30758919.s1.e1" /></sentence><sentence text="Lesinurad is a selective uric acid reabsorption inhibitor approved for use in combination with xanthine oxidase inhibitors for the treatment of hyperuricemia associated with gout"><entity charOffset="0-9" id="DDI-PubMed.30758919.s2.e0" text="Lesinurad" /><entity charOffset="25-34" id="DDI-PubMed.30758919.s2.e1" text="uric acid" /><entity charOffset="95-103" id="DDI-PubMed.30758919.s2.e2" text="xanthine" /><pair ddi="false" e1="DDI-PubMed.30758919.s2.e0" e2="DDI-PubMed.30758919.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30758919.s2.e0" e2="DDI-PubMed.30758919.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30758919.s2.e0" e2="DDI-PubMed.30758919.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30758919.s2.e1" e2="DDI-PubMed.30758919.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30758919.s2.e1" e2="DDI-PubMed.30758919.s2.e2" /></sentence><sentence text=" In vitro, lesinurad was shown to be a weak inhibitor of cytochrome P450 (CYP)2C9 and a weak inducer of CYP3A4"><entity charOffset="11-20" id="DDI-PubMed.30758919.s3.e0" text="lesinurad" /></sentence><sentence text=" Warfarin is a widely prescribed oral coumarin-based anticoagulant commonly prescribed in gout patients"><entity charOffset="1-9" id="DDI-PubMed.30758919.s4.e0" text="Warfarin" /><entity charOffset="38-46" id="DDI-PubMed.30758919.s4.e1" text="coumarin" /><pair ddi="false" e1="DDI-PubMed.30758919.s4.e0" e2="DDI-PubMed.30758919.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30758919.s4.e0" e2="DDI-PubMed.30758919.s4.e1" /></sentence><sentence text=" In an open-label clinical study in healthy adult male subjects, the effects of multiple daily doses of 400 mg lesinurad on the pharmacokinetics and pharmacodynamics of a single dose of 25 mg warfarin (racemic mixture of R- and S- enantiomers) were evaluated"><entity charOffset="111-120" id="DDI-PubMed.30758919.s5.e0" text="lesinurad" /></sentence><sentence text=" Lesinurad had no effect on the absorption or the exposure (area under the concentration-time curve [AUC] and peak concentration) of the more active S-warfarin enantiomer"><entity charOffset="1-10" id="DDI-PubMed.30758919.s6.e0" text="Lesinurad" /><entity charOffset="149-159" id="DDI-PubMed.30758919.s6.e1" text="S-warfarin" /><pair ddi="false" e1="DDI-PubMed.30758919.s6.e0" e2="DDI-PubMed.30758919.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30758919.s6.e0" e2="DDI-PubMed.30758919.s6.e1" /></sentence><sentence text=" A slight reduction (19%) in overall plasma exposure (AUC) was observed for the R-warfarin enantiomer"><entity charOffset="80-90" id="DDI-PubMed.30758919.s7.e0" text="R-warfarin" /></sentence><sentence text=" Lesinurad had no meaningful clinical impact on anticoagulation activity as measured by prothrombin time, activated partial thromboplastin time, and international normalized ratio of prothrombin time and Factor VII clotting activity"><entity charOffset="1-10" id="DDI-PubMed.30758919.s8.e0" text="Lesinurad" /></sentence><sentence text=" Overall, the administration of warfarin in the presence of multiple-dose lesinurad was devoid of clinically significant drug-drug interaction"><entity charOffset="32-40" id="DDI-PubMed.30758919.s9.e0" text="warfarin" /></sentence><sentence text="" /></document>